延迟抗逆转录病毒治疗对未治疗HIV感染者抗CD4自身抗体的影响
在START试验中,1199例CD4>500 cells/µL的未治疗HIV感染者随机立即或延迟启动ART,基线抗CD4自身抗体阳性率41%,24个月时立即组降至26%、延迟组降至31%(OR=2.04,P<.001)。基线抗CD4自身抗体与立即组CD4恢复无关。
要点
- 未治疗且CD4>500 cells/µL的HIV感染者中抗CD4自身抗体常见,基线阳性率41%。
- 启动ART后抗CD4自身抗体阳性率下降,延迟启动组24个月阳性率更高。
- 基线抗CD4自身抗体不影响CD4>500 cells/µL者启动ART后的CD4恢复。
核心结论
- 抗CD4自身抗体在未治疗且CD4计数高的HIV感染者中常见,使用ART后其阳性率下降。
- 在CD4>500 cells/µL启动ART的HIV感染者中,抗CD4自身抗体与CD4恢复无关。
研究设计与样本
- START试验中ART未治疗且CD4>500 cells/µL的HIV感染者随机分为立即启动ART组或延迟至CD4<350 cells/µL或AIDS时启动ART组。
- 在1199例参与者(立即组600例,延迟组599例)中,用LIPS法检测基线和第24个月血浆抗CD4自身抗体。
主要发现
- 基线抗CD4自身抗体总阳性率为41%,近期HIV感染者和非洲参与者中更高。
- 第24个月抗CD4自身抗体阳性率在立即组降至26%,延迟组降至31%(OR=2.04;P<.001)。
- 近期HIV感染者抗CD4自身抗体下降幅度更大(P<.001)。
- 立即组内,基线抗CD4自身抗体状态与第24个月CD4计数较基线的平均变化无关。
关键数值与推荐
- 基线抗CD4自身抗体阳性率41%(1199例参与者)。
- 第24个月抗CD4自身抗体阳性率立即组26%、延迟组31%,延迟组 vs 立即组OR=2.04,P<.001。
临床怎么用
- 对于CD4>500 cells/µL的未治疗HIV感染者,抗CD4自身抗体普遍存在,但启动ART后下降。
- 不应将基线抗CD4自身抗体作为CD4>500 cells/µL者启动ART后CD4恢复的预测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously identified anti-CD4 autoantibodies in antiretroviral therapy (ART)-naive people with Human Immunodeficiency Virus (HIV) (PWH) with CD4 < 100 cells/µL using luciferase immunoprecipitation systems (LIPSs). The influence of ART initiation on anti-CD4 autoantibodies and their impact on CD4 recovery in PWH with higher CD4 counts are unclear. METHODS: In the Strategic Timing of Antiretroviral Treatment (START) trial, ART-naive PWH with CD4 > 500 cells/µL were randomized to start ART immediately (immediate) or delay until CD4 < 350 cells/µL or Acquired Immunodeficiency Syndrome (AIDS) (deferred). In a subset of participants, we measured anti-CD4 autoantibodies using LIPS from plasma samples collected at baseline and month 24. We used logistic regression models to evaluate associations with the presence of anti-CD4 autoantibodies and to compare month 24 anti-CD4 autoantibodies between treatment groups. In the immediate group, the mean change in CD4 counts from baseline to month 24 was compared by baseline anti-CD4 autoantibody serostatus. RESULTS: Baseline anti-CD4 autoantibody prevalence in 1199 participants (600 immediate, 599 deferred) was 41%; anti-CD4 autoantibodies were higher with recent HIV infection and among participants in Africa. At month 24, anti-CD4 autoantibody prevalence had decreased to 26% in the immediate and 31% in the deferred group (odds ratio [OR] = 2.04; P < .001). Participants with recent HIV infection had larger decreases in anti-CD4 autoantibodies (P < .001). There was no difference in CD4 recovery from baseline to month 24 by baseline anti-CD4 autoantibodies within the immediate group. CONCLUSIONS: Anti-CD4 autoantibodies are common in untreated PWH with high CD4 counts; however, with ART use, their prevalence decreases. Anti-CD4 autoantibodies are not associated with CD4 recovery in PWH with CD4 > 500 cells/µL initiating ART.
引用
- Epling BP, Mistry S, Grund B, et al. Effect of Delayed Antiretroviral Therapy Initiation on Anti-CD4 Autoantibodies in Antiretroviral Therapy-Naive People With HIV. J Infect Dis. 2026. PMID: 42047100. doi:10.1093/infdis/jiag235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。